Close Menu

More articles about Business News

The molecular diagnostics firm expects to close the placement of newly issued common shares today.

Interleukin said that it would directly place the shares and purchase warrants with institutional investors. Its shares dropped sharply in early Friday trade.

The decision paves the way for Enzo to be issued a patent based on its prior application, and the company plans to "rapidly" develop and market products based on the technology for a wide variety of applications.

Shares of Interleukin rose after the firm said that the results of a retrospective study suggest that individuals who base their diet on genotype could potentially benefit from the firm's weight management genetic test.

PioneerBiomed will distribute the Duolink line to public and private research communities in China.

Celera posted a profit, even though its Q4 revenues declined due to lower sales from its lab services business. The firm also guided for lower 2010 revenues than the market had previously expected due to issues surrounding that part of its business.

Alnylam's top official said that while the company is encouraged that it will be able to confirm efficacy data observed in a phase IIa trial of its respiratory syncytial virus treatment ALN-RSV01, he stressed that it may not be able to do so in a follow-up study initiated late last month.

As part of its request for dismissal, MIT admitted no wrongdoing, but agreed to be bound by any court ruling against the case's other defendants, the Whitehead Institute for Biomedical Research and the University of Massachusetts Medical School.

IP Update: Mar 4, 2010

Premium

USPTO Publishes One Patent, Ten Patent Applications Related to RNAi

The exclusive agreement covers the RapidFire systems and screening.

The firm also retired a potentially dilutive reserve of approximately 1.1 million shares of common stock that could have been issued in the conversion of the debt.

An analyst placed a $16 price target on Sequenom's shares, which closed at $6.92 yesterday.

The test was licensed from Toronto's Centre for Addiction and Mental Health. It expects the test to hit the market next year.

The German firm will offer Polyplus-transfection's new ZNA technology, which it said increases the affinity for nucleic acids.

The patent office was aiming to determine who invented technology first related to nucleic acid signal amplification.

Congenital Cardiac Union

Premium

NHLBI has united leading hospitals with a six-year grant to study the genetic and epigenetic causes of congenital heart disease.

Millennium Science will distribute the SNP and Variation Suite to life sciences customers in Australia and New Zealand.

PerkinElmer has purchased the ICP-MS joint venture from Danaher that was at the center of PerkinElmer's earlier legal action against MDS.

The company will work with Semmelweis University to develop micromethods for handling small biosamples for microarray analysis.

The firm, formerly known as Strategic Diagnostics, saw an increase in kit sales, but not enough to offset a 21 percent decline in life science revenue.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.